| Professional Services Industry | Industrials Sector | Su-Leng Tan CEO | NASDAQ (CM) Exchange | 090628306 CUSIP |
| MY Country | 30 Employees | - Last Dividend | - Last Split | - IPO Date |
BioNexus Gene Lab Corp., founded in 2017 and headquartered in Kuala Lumpur, Malaysia, operates primarily through its subsidiary to distribute chemical raw material products across Malaysia, Indonesia, Vietnam, and other Southeast Asian countries. While its main business centers around the provision of chemical raw materials used in various manufacturing processes, the company has expanded its operations to include the development and provision of non-invasive liquid biopsy tests. These tests are designed for the early detection of biomarkers, which could indicate a potential risk of diseases. With its diverse product offerings, BioNexus Gene Lab Corp. serves a wide range of industries, including the automotive, aerospace, healthcare, and marine sectors. The company markets its products and services through multiple channels including its website, a physical warehouse, a team of marketing personnel, and a network of suppliers.
A thixotropic, quick-curing unsaturated polyester resin that is marketed as a general-purpose resin. This material finds its application in various manufacturing processes due to its versatile properties.
This general-purpose material is primarily used in the production of marine boats and water slides, showcasing its strength in environments where durability and resistance to water are crucial.
Utilized as a component in the pultrusion process by certain manufacturers, this resin is integral in the creation of strong, lightweight products. Applications include handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms. It is also used in the production of covers for various instruments used in manufacturing, highlighting its versatility and wide range of applications.
In addition to its chemical products, BioNexus is involved in the development and provision of innovative non-invasive liquid biopsy tests. These tests aim for early detection of biomarkers for potential disease risk, reflecting the company's engagement in healthcare and biotechnology sectors alongside its chemical manufacturing operations.